Name： DENG Hongbin

Department：Biochemistry

Tel: (8610) 63169876

Email: hdeng@imb.pumc.edu.cn

Education & Research Experience

Education

2001/09 - 2004/07,  Ph.D. in Microbiology and Biochemical Pharmacy, Peking Union Medical College & Chinese Academy of Medicinal Sciences

1998/09-2001/06,  M.S in Microbiological and Biochemistry Pharmacy, Shenyang Pharmaceutical University

1994/09-1998/06,  B.S in Microbiological Pharmacy, Shenyang Pharmaceutical University

Research Experience

2018/09 – Now, Professor,  Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College

2010/09 –2018/08, Associate Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College

2008/02–2010/08, Assistant Professor, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College

2005/01 – 2008/01, Postdoctoral fellow, Ben May Department for Cancer Research, The University of Chicago

Research Field：Decipher the tumor immune evasive mechanisms and develop new molecules and combinations for immune-oncology targets

Research Interests：The central research focus of our lab is to examine the intimate dialogues between cancer cells and tumor microenvironment by comprehensive understanding of tumor immune evasive mechanisms, and translate this mechanistic understanding to develop small molecule drugs as the next generation of immunotherapy. To this end, we are developing small molecules that disrupt immune checkpoint PD-1/PD-L1 axis, and small molecules that attenuate the functions of TAM, MDSCs and Tregs within tumor microenvironment, to restore anti-tumor immunity.

Selected Publications

1. Mingxiao Yin,^# Jingwen Dong,^# Cuicui Sun, Xiaojia Liu, Zhirui Liu, Lu Liu, Zean Kuang, Na Zhang, Dian Xiao, Xinbo Zhou,^* and  Hongbin Deng^*. RaddeaninA Enhances Mitochondrial DNA-cGAS/STING Axis-Mediated Antitumor Immunity by Targeting Transactive Responsive DNA-Binding Protein 43. Advanced Science, 2023,10 (13): e2206737. （IF=17.521）

2. Chengliang Sun,^# Mingxiao Yin,^# Yao Cheng,^# Zean Kuang, Xiaojia Liu, Gefei Wang, Xiao Wang, Kai Yuan, Wenjian Min, Jingwen Dong, Yi Hou, Lingrong Hu, Guoyu Zhang, Wenli Pei, Liping Wang, Yanze Sun,Xinmiao Yu, Yibei Xiao,^* Hongbin Deng,^* and Peng Yang^*. Novel Small-Molecule PD-L1 Inhibitor Induces PD-L1 Internalization and Optimizes the Immune Microenvironment. Journal of Medicinal Chemistry, 2023,66 (3): 2064-2083.（IF=8.039，cover article）

3. Chengliang Sun^#, Yao Cheng^#, Xiaojia Liu^#, Gefei Wang,Wenjian Min, Xiao Wang, Kai Yuan, Yi Hou, Jiaxing Li, Haolin Zhang, Haojie Dong, Liping Wang, Chenguang Lou, Yanze Sun, Xinmiao Yu, Hongbin Deng^*, Yibei Xiao^*, Peng Yang^*.  Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents. Acta Pharmaceutica Sinica B, 2022,12 (12):4446-4457.（IF=14.907）

4. Xiaojia Liu^#, Mingxiao Yin^#, Jingwen Dong, Genxiang Mao, Wenjian Min, Zean Kuang, Peng Yang,Lu Liu, Na Zhang, Hongbin Deng^*. Tubeimoside-1 induces TFEB-dependent lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting mTOR. Acta Pharmaceutica Sinica B, 2021,11(10) : 3134-3149.（IF=14.907）

5. Yang Liu^#, Xiaojia Liu^#, Na Zhang^#, Mingxiao Yin, Jingwen Dong, Qingxuan Zeng, Genxiang Mao,Danqing Song, Lu Liu^*, HongbinDeng^*. Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5. Acta Pharmaceutica Sinica B, 2020, 10 (12 ): 2299-2312. （IF=11.614）

6. Qingxuan Zeng^#, Hongbin Deng^#, Yinghong Li^#, Tianyun Fan, Yang Liu, ShengTang, Wei Wei, Xiaojia Liu, Xixi Guo, Jiandong Jiang, Yanxiang Wang^*, Danqing Song^*. Berberine Directly Targets the NEK7 Protein to Blockthe NEK7- NLRP3 Interaction and Exert Anti-inflammatory Activity, Journal of Medicinal Chemistry, 2021, 64(1): 768-781.（IF=8.039）

7. Na Zhang^#, Yueying Dou^#, Lu Liu, Xin Zhang, Xiaojia Liu, Qingxuan Zeng, Yang Liu, Mingxiao Yin, Xiujun Liu, Hongbin Deng^* and Danqing Song^*. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1. EBioMedicine. 2019, 40:151-162. （IF=6.680）

8. Xiaojia Liu^#, Na Zhang^#, Yang Liu, Lu Liu, Qingxuan Zeng, Mingxiao Yin,Yanxiang Wang, Danqing Song^*, and Hongbin Deng^*. MPB, a novel Berberine derivative, enhances lysosomal and bactericidal properties via TGF-β-activated kinase 1-dependent activation of the transcription factor EB. The FASEB Journal, 2019, 33(1):1468-1481.（IF=5.573）

9. Lu Liu^#, Yang Liu^#, Xiaojia Liu, Na Zhang, Genxiang Mao, Qingxuan Zeng, Mingxiao Yin,Danqing Song, Hongbin Deng^*. Resibufogenin suppresses TAK1-mediated NF-κB activity via protein kinase C-dependent inhibition of glycogen synthase kinase 3. Cancer Science, 2018, 109: 3611-3622.（IF=4.751）

10. Xin Zhang^#, Qiang Liu^#, Na Zhang, Qian-Qian Li, Zhan-Dong Liu, Ying-Hong Li, Li-Mei Gao, You-Chun Wang, Hong-Bin Deng^*, Dan-Qing Song^*. Discovery and evolution of aloperine derivatives as novel anti-filovirus agents through targeting entry stage. European Journal of Medicinal Chemistry, 2018, 149: 45-55.   (IF=4.833）

11. Na Zhang^#, Xiaojia Liu^#, Lu Liu, Zhesong Deng, Qingxuan Zeng, Weiqiang Pang, Yang Liu, Danqing Song^*, Hongbin Deng^*. Glycogen synthase kinase-3β inhibition promotes lysosome-dependent degradation of c-FLIPL in hepatocellular carcinoma. Cell Death & Disease, 2018, 9(2):230. （IF=5.959）

12. Yan-xiang Wang^#, Weiqiang Pang^#, Qing-xuan Zeng, Zhe-song Deng, Tian-yun Fan,Jian-dong Jiang, Hongbin Deng^*, Dan-qing Song^*, Synthesis and biological evaluation of new berberine derivatives as cancer immunotherapy agents through targeting IDO1.  European Journal of Medicinal Chemistry, 2018, 143:1858-1868.  (IF=4.833）

13. Lu Liu , Na Zhang , Yueying Dou, Genxiang Mao, Chongwen Bi ,Weiqiang Pang , Xiaojia Liu , Danqing Song^*, Hongbin Deng^*. Lysosomal dysfunction and autophagy blockade contribute to IMB-6G-induced apoptosis in pancreatic cancer cells. Scientific Reports, 2017, 7:41862. （IF=4.122）

Awards and Honors

2019 Science and Technology award of Chinese pharmaceutical association, second class.

2016 Science and Technology award of Chinese pharmaceutical association, second class.

2012 Sanofi youth biological medicine prize of Chinese pharmaceutical association.

2005 Beijing Science and Technology Advancement Award, third class.

Academic Appointments

Member of Committee of Anti-Cancer Agent, China anti-cancer association

Member of Geriatric Pharmacy Professional Committee, Chinese pharmaceutical association